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Pivotal and Continued Access Trials.
METHODS Patients in the CoreValve US Pivotal and Continued Access
trials were examined with respect to whether they underwent balloon
dilation of the CoreValve frame after valve implantation. Clinical,
anatomic, procedural and outcome data were analyzed. Best practice
guidelines in these trials recommended pre-dilation of the native
valve prior to CoreValve deployment, with BPD of the CoreValve
frame reserved for treatment of suboptimal intraprocedural stent
valve function.
RESULTS Procedural BPD was performed in 782 of 3532 patients (22%).
Male sex, larger aortic annular diameters, greater baseline aortic gra-
dients and aortic regurgitation (AR) were seen in the patients who
underwent balloon post-dilation (Table). The incidence of balloon pre-
dilation of the native valve and the CoreValve implant depth were
similar between those who did and did not undergo BPD. BPD was
performed less frequently with the 26 mm valve (17.9%) as compared to
the 31 mm valve (38.0%). The most common indication for BPD was 
moderate AR following CoreValve deployment which accounted for
58.1% of BPD patients. BPD was effective in acutely reducing AR in the
majority of these patients, with 78.0% with moderate AR having mild
or no AR after BPD. In-hospital major adverse cardiovascular and ce-
rebrovascular event rates were similar between no BPD (7.5%) and BPD
(9.3%) groups; p¼0.10. One case of valve migration and 3 cases of fatal
cardiac perforation occurred following BPD.
Table. Baseline CharacteristicsNo BPD
N [ 2750BPD
N [ 782 P ValueAge (years) 83.3  7.7 83.6  7.9 0.30
Female sex 49.3 % 37.5 % <0.0001Mean annular diameter
(mm)24.4  2.2 25.2  2.2 <0.0001Annular sizing ratio
<10%12.2% 24.0% <0.0001Mean aortic gradient
(mmHg)41.3  15.7 44.8  16.5 <0.0001Baseline AR 
moderate13.9% 21.5% <0.0001CONCLUSIONS Balloon post-dilation of the CoreValve bioprosthesis
was performed in 22% of patients in the CoreValve US Trials, most
commonly in patients with larger valve annulus measurements and
those with more severe baseline aortic valve dysfunction. The most
frequent indication for balloon post dilation was moderate or severe
aortic regurgitation. Balloon post-dilation was effective in acutely
improving valve performance and reducing aortic valve regurgitation
in the majority of these patients.
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BACKGROUND The long-term performance of SAPIEN transcatheter
aortic valve replacement (TAVR) is not known. Therefore, we exam-
ined the hemodynamic proﬁle of SAPIEN TAVR over 5 years of
follow-up and compared these results with surgical bioprosthetic
aortic valve replacement (SAVR).METHODS All patients receiving SAPIEN TAVR or SAVR with ﬁrst
post implant (FPI) and 5-year echoes were analyzed by an indepen-
dent echo core lab for: aortic valve (AV) peak velocity, AV mean
gradient, AV area (AVA), AVA indexed for body surface area, pre-stent
velocity in the left ventricular outﬂow tract (LVOT), in-stent (pre-
leaﬂet) velocity, time velocity integrals (TVI), Doppler velocity index
(DVI) and total, transvalvular and paravalvular aortic regurgitation
(AR). FPI and 5-year data were compared using paired t-test and
McNemar’s analyses.
RESULTS 91 SAPIEN TAVR and 48 SAVR patients had AV hemody-
namic assessments on FPI and 5 year echoes (Figure). AVA and AVA
index were unchanged 5 years after SAPIEN TAVR (p¼0.59 and
p¼0.72). AV mean gradient also did not change: 11.85.6 mmHg at
FPI to 10.96.1mmHg at 5 years, p¼0.21. In contrast, peak LVOT and
AV velocities decreased (both p¼0.02), as did in-stent velocity,
p¼0.01. Correspondingly, TAVR DVI using LVOT TVI or in-stent TVI
were unchanged, p¼0.16 and p¼0.09, respectively. There was no
signiﬁcant change in overall total AR (p¼0.32), paravalvular AR
(p¼0.11) or transvalvular AR (p¼0.71) over time among TAVR
patients. The results of longitudinal hemodynamic evaluation of
SAVR patients were similar to that seen in patients receiving
SAPIEN TAVR.
CONCLUSIONS Independent longitudinal assessment of the SAPIEN
TAVR shows that valve hemodynamics are stable 5 years after im-
plantation and similar to those for SAVR. These results indicate good
long term durability and support the use of TAVR in high-risk
patients.
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BACKGROUND Self-expanding transcatheter aortic valve replace-
ment (TAVR) is superior to medical therapy for pts with severe native
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5 B45AV stenosis unsuitable for surgery. We are reporting 6 month out-
comes in TAVR pts with a failed surgical bioprosthesis who were un-
suitable for open surgery.
METHODS The CoreValve US Expanded Use Study is a prospective, non-
randomized, single arm study that evaluates safety and effectiveness of
TAVR in complex subsets of extreme risk pts including those who are
symptomatic with failed surgical bioprosthesis. Baseline echocardio-
graphic data were reported by the sites, while an independent core lab
evaluated all follow-up ﬁndings. The primary endpoint was a composite
of all-cause mortality or major stroke rate at 1 year.
RESULTS From Mar 2013 – Oct 2014, 143 pts had an attempted
implant. Surgical failure mode was stenosis 59%, regurgitation 24%,
combined 17%. 141/143 (98.6%) pts had successful TAVR implantation
with 2 aborted procedures. Pts were elderly 77  11 years, 66% were
men, STS PROM 9.4  6% and severely symptomatic (NYHA III/IV
87%). All-cause mortality or major stroke at 6 mo was 10.7% (mortality
9%, major stroke 1.8%). 6mo Mod/Sev PVL 1.2% & NYHA III/IV 3.4%.
Permanent pacemaker rate was 8.3%.
CONCLUSIONS CoreValve TAVR in pts with failed surgical bio-
prosthesis at extreme risk for surgery was associated with a low 6 mo
mortality and stroke rate, signiﬁcant reduction in aortic valve gradi-
ents, and a low incidence of moderate/severe PVL and NYHA III/IV
failure.
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BACKGROUND Transcatheter aortic valve replacement has become
the default treatment for patients with severe aortic stenosis at
extreme or high risk for surgery. Extrapolation of the safety and ef-
ﬁcacy established in the CoreValve US Pivotal trials has not been
conﬁrmed after regulatory approval. The objective of this study was to
report the 30-day clinical outcome of patients treated with the Cor-
eValve self-expanding bioprostheses in commercial practice.
METHODS A total of 4913 patients with severe aortic stenosis
implanted with the self-expanding CoreValve at 186 US centers be-
tween January 2014 and March 2015 were included in the Trans-
catheter Valve Therapies (TVT) Registry (extreme risk (ER), 41.5%;
high risk (HR), 53.3%; intermediate risk, 3.6%; other; 1.6%). Patientswere followed for at least 30 days for Valve Academic Research Con-
sortium criteria for mortality and major complications.
RESULTS The 30-day results of the TVT Registry are found in the Table.
A transfemoral approach was used in 89.4% of patients. CoreValve sizing
recommended by CTA included: 23 mm, 4.3%; 26 mm, 22.4%; 29 mm,
38.8%; 31 mm, 34.5%. For discussion, the combined results of the
CoreValve US Pivotal Extreme Risk and High Risk Trials are provided
(Popma JACC 2014, Adams, NEJM 2014) (Table). No statistical
comparisons were performed with the TVT Registry due to the differing
patient populations, data collection and enrollment periods.
CONCLUSIONS This ﬁrst report of the TVT Registry provides assur-
ance of the early safety and effectiveness of the CoreValve self-
expanding bioprosthesis in clinical practice. Longer-term follow-up is
needed to establish the extended beneﬁt in these patients.
TableVariableTVT Registry
N[4,913ER/HR Pivotal Study
N[1,030BaselineAge, years / STS PROM, % 81.1 / 8.8 83.0 / 9.2Diabetes, % / Prior CABG, % 38.4 / 30.1 37.9 / 35.8CAD, % / Prior Pacemaker, % 70.1 / 21.8 79.1 / 24.9Mean AV gradient Pre / Post,
mmHg43.3 / 8.4 48.0 / 9.730-Day EventsAll-cause Mortality, % / Any
Stroke, %5.3 / 2.8 6.9 / 5.0Major Vascular, % / New PPM,
%1.1 / 22.3 7.5 / 20.2Device Thrombosis, % /
Fracture, %0 / 0 0 / 0PVL*, % / Valve-in-Valve, % 9.8 / 3.2 10.5 / 2.6Device Implanted Successfully,
%98.0 98.9CABG ¼ coronary artery bypass surgery; CAD ¼ coronary artery disease; STS PROM¼ STS Predicted Risk of
Mortality; *Moderate or severe.
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BACKGROUND The repositionable CoreValve Evolut R transcatheter
aortic valve (TAV) was designed to permit optimal valve placement at
the desired plane of the native aortic valve and depth of implant. The
Evolut R TAV (26, 29 mm) obtained CE marking after demonstrating
safety and efﬁcacy at 30 days in patients with symptomatic aortic
stenosis and heart-team assessed risk of operative mortality. Out-
comes at 1 year will be available at the time of the meeting.
METHODS The Evolut R CE Study included 60 patients implanted at 6
sites in Australia, New Zealand and the United Kingdom and included
the ﬁrst use of the valve for all operators. An independent echocar-
diographic core laboratory was employed, and Clinical Events Com-
mittee adjudicated major adverse events according to Valve Academic
Research Consortium-2 criteria. Major adverse events, functional
improvement, and valve performance were assessed early post-pro-
cedure, at 30 days, 6 months, and 1 year.
RESULTS A total of 60 patients were enrolled and all received the
Evolut R TAV; mean age was 82.8 6.1 years; 66.7% were women,
68.3% had New York Heart Association (NYHA) III/IV symptoms, and
the mean STS-PROM was 7.0%3.7%. The majority of patients (68.3%)
were considered frail. The repositioning feature of the Evolut R was
successfully used 22 times in 15 patients. There were no deaths at 30
days and all-cause mortality at 6 months was 5.0%. One disabling
stroke occurred between 30-day and 6-month follow-up. There were
no valve embolization, migration, endocarditis or thrombosis events,
and no coronary obstruction. The Evolut R TAV effectively treated the
